KOLThis boards consensus is the information was positive, only wish the market and the FDA shared the same opinion. Without FDA granting AA ,and why wouldn't they, with such a difficult disease to treat and few options available, or the announcement of a partner or buyout the response will continue to be muted. This has been the storyline of this company for so many years beginning with the head and neck back in 2008. They just can't get any traction to see the share price rise to the levels required to garner any instutional investor interest or a BP and one wonders why when this boards response is so overwhelmingly positive. Let's hope they are negotiating with more than one BP otherwise the prospects of a happy ending are growing even more remote. No money to conduct a PIII themselves leaves very few options. This is the reality and they better move quick, time is money.